Litcius/Paper detail

Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic

Zeynab Fakhar, Bahar Faramarzi, Severina Pacifico, Shadab Faramarzi

2020Journal of Biomolecular Structure and Dynamics44 citationsDOI

Abstract

enzyme plays a key role in mediating viral replication and transcription and thus being considered as an attractive drug target. Herein, comprehensive computational investigations were performed to identify new lead compounds against main protease enzyme. In this study, the candidate anthocyanin-derived compounds from PubChem database were filtered considering antiviral characteristics of anthocyanins. The structure-based pharmacophore modeling was developed based on the co-crystallized structure of the enzyme with its biological active inhibitor. The generated hypotheses were applied for virtual screening-based PHASE Screen Score. Docking based virtual screening work flow was used to generate hit compounds using HTVS, SP and XP based Glide Gscore. The obtained hit compounds were filtered using ADMET pharmacological and physicochemical properties screening. Molecular dynamics simulations were performed to explore the binding affinities of the considered compounds. Our study identified six best anthocyanin-derived natural compounds which could be used as promising lead compounds against main protease SARS-CoV-2 virus.

Topics & Concepts

Virtual screeningPharmacophorePubChemIn silicoProteaseComputational biologyDrug discoveryDrug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Docking (animal)CoronavirusAntiviral drugVirologyEnzymeDrugBiologyCoronavirus disease 2019 (COVID-19)ChemistryPharmacologyBiochemistryMedicineInfectious disease (medical specialty)GeneDiseasePathologyNursingComputational Drug Discovery MethodsDiverse Scientific Research StudiesEssential Oils and Antimicrobial Activity
Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic | Litcius